Apretude TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: cabotegravir
Brand name
(ARTG)
: APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
APRETUDE is indicated in at-risk adults and adolescents (at least 12 years of age) and weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.,APRETUDE tablets may be used as an oral lead-in to assess tolerability of cabotegravir prior to administration of cabotegravir injections or as short-term oral PrEP in individuals who will miss planned dosing with cabotegravir injections.,Individuals must have a documented negative HIV-1 test prior to initiating APRETUDE for HIV-1 PrEP.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, suspension
- Intramuscular
- white to light pink suspension
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Do not Freeze
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 vial 600 mg/3 mL cabotegravir pack
- 25 x 1 vial 600 mg/3 mL cabotegravir pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient cabotegravir
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
